Ashwin Gollerkeri

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero, Axel Grothey, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2021 · 544 citations · Full text

Medicine, Oncology, Pharmacology +16

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

Jörge E. Cortes, Philippe Rousselot, Dong‐Wook Kim et al. · Blood · 2006 · 418 citations

Medicine, Hematology, Oncology +16

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

François Guilhot, Jane F. Apperley, Dong‐Wook Kim et al. · Blood · 2007 · 372 citations · Full text

Medicine, Hematology, Oncology +14

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

Oliver G. Ottmann, Hervé Dombret, Giovanni Martinelli et al. · Blood · 2007 · 369 citations · Full text

Life Sciences, Hematology, Oncology +16